目前,大多数人相信用DDS,B663和RFP联合化疗治疗麻风病是可靠的。但是,麻风菌对这些药的每一种都有耐药的报道,DDS是抑制剂,B663有不利的副作用,即皮肤色素沉着。RFP是可靠的杀菌药物,但是价格太贵。因此,需要发展新的,与现有的抗麻风药无交叉耐药、有杀菌作用、毒性小和比RFP价格低的抗麻风药。 At present, most people believe that the combination of DDS, B663 and RFP chemotherapy for the treatment of leprosy is reliable. However, leprosy has been reported to be resistant to each of these drugs, DDS being an inhibitor, and B663 has an adverse side effect of skin pigmentation. RFP is a reliable bactericide, but it’s too expensive. There is therefore a need to develop new anti-leprosy drugs that are not cross-resistant to existing anti-leprosy agents, have a bacteriocidal effect, are less toxic and less expensive than RFP.